Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
Watson Pharmaceuticals has bought Greek generics firm Specifar Pharmaceuticals, bringing to an end a busy month of deal making in the non-branded drug sector.
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.
Oystar has sold its processing tech units, Huttlin and Manesty, to Bosch in a deal that continues its effort to refocus on primary and secondary packaging.
Nano Terra, a surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer, Surface Logix.
Pharmaceutical giant Pfizer has agreed to sell Capsugel, its drug delivery technology unit, to US investment group Kohlberg Kravis Roberts & Co (KKR) for $2.4bn (€1.7bn).
Gerresheimer has bought Brazilian pharmaceutical plastic packaging maker Vedat, citing rapid growth of the country’s drug market, particularly the generics segment, as the main driver for the acquisition.
Tokyo, Japan-based digital imaging specialist, Fujifilm, has agreed a deal to buy US drug giant Merck and Co's BioManufacturing Network, including two biotech manufacturing plants.
Pfizer has acquired the consumer healthcare business of Danish firm Ferrosan for an undisclosed fee in what the pharma giant says, “is an excellent strategic fit that strengthens our presence in dietary supplements”.
Sigma-Aldrich has acquired analytical standards and certified reference materials manufacturer Resource Technology Corporation (RTC) to expand its analytical
Expansion has been a theme for German pharmaceutical packaging firms of late with the acquisition of Seidenader Maschinenbau by the Kober Group following just weeks after Edelmann bought a stake in Hungary’s Zalai Nyomda
NextPharma Technologies will be bought by Sun European Partners, the European adviser to US investment group Sun Capital Partners, in a deal announced late yesterday.
in-Pharmatechnologist presents a roundup of the latest deals and acquisitions in the pharmaceutical sector with news from Optima, SPI and DPS Engineering.
Big pharma continued to cut in 2010, closing plants and laying off staff in an attempt to cut costs and adjust post-merger. in-PharmaTechnologist presents a round up of five of the most read in 2010.
US based healthcare distributer, Cardinal Health, has announced the $470m acquisition of privately held healthcare distribution business Zuellig Pharma China, known locally as Yong Yu.
GlaxoSmithKline will sell its oral penicillin manufacturing facility in Tennessee, US, to Dr Reddy’s for an undisclosed sum, along with US rights to its Augmentin and Amoxin brands.
Camlin Fine Chemicals has been given the green light from its board of directors to acquire an unnamed Italian fine chemicals manufacturer and form a subsidiary company to help boost its presence in the Middle East.
Rumours suggest that Genzyme would consider accepting lower value takeover bids that take into account future performance of its cancer drug Campath in MS indications.
Roche will cut 4,800 jobs worldwide over the next two years as part of a restructuring program designed to slash $2.4bn Swiss francs ($2.4bn) from annual costs.
API maker AMRI cited arbitration costs, efforts to address a US FDA warning letter and acquisitions as key factors in Q3 loss, but predicted that large-scale contract manufacturing business will drive final quarter gains.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.